McDermott et al. [46] in their study observed that the levels of M-CSF were significantly higher in patients with newly diagnosed tumors of the head and neck, men with prostate cancer metastatic to bone, and women with advanced metastatic breast cancer when compared to those with newly diagnosed breast tumors. This evidence concerns the gene CSF1 and prostate cancer.